Develops immune therapies for cancer patients and people with autoimmune diseases, including treatments that direct immune cells against tumors.
10-K for FY2025, filed Feb 26, 2026
Janux earns collaboration revenue through upfront payments and research funding; it may receive further payments when development or sales milestones are reached, as well as royalties on sales of licensed products.
10-K for FY2025, filed Feb 26, 2026On December 15, 2020, we and Merck Sharp & Dohme Corp. (Merck), entered into a research collaboration and exclusive license agreement (the…View ↗
In consideration of the rights granted to Merck under the Merck Agreement, Merck paid us a one-time upfront payment of $8.0 million in…View ↗
In December 2020, we entered into a research collaboration and exclusive license agreement with Merck to develop TRACTr product candidates…View ↗
In December 2020, we entered into a research collaboration and exclusive license agreement with Merck to develop TRACTr product candidates…View ↗
$10M
10-K for FY2025, filed Feb 26, 2026
$10M ↗
Janux works with pharmaceutical companies through research collaborations and licenses; Merck holds exclusive worldwide licenses to selected cancer targets.
10-K for FY2025, filed Feb 26, 2026
No. It lost $113.6M in FY2025.
Growing. Revenue grew 2.7x in 4 years, from $3.6M in FY2021 to $10M in FY2025, about 29% a year.
Broader disease focus
The latest report describes an immune-modulating program for autoimmune diseases, beyond the older report's cancer-focused TRACTr and TRACIr pipeline.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Feb 26, 2026
Competes with AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead, GSK, Johnson & Johnson, Merck &, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Takeda, and Roche/Genentech
10-K for FY2025, filed Feb 26, 2026We compete in the segments of pharmaceutical, biotechnology, and other related markets that develop immuno-oncology and autoimmune disease…View ↗
Loading...